<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="4957" end="4961" sStart="4954" offset="3" sid="r7.1.use.v.0519" wn="1" wnkey="use%2:34:01::" annotator="brubin" text="We used the MTT assays to assess the viability of the tumor cells treated with or without the drug." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-2-1.anc" start="8741" end="8752" sStart="null" offset="0" sid="null" wn="3" wnkey="transfer%2:38:05::" annotator="tofox" text="The proteins were &lt;b&gt;transferred&lt;/b&gt; onto nitrocellulose membrane, and the PDGFR-? was detected with anti-PDGFR-? antibody (Santa Cruz Biotechnologies Inc.)." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1476-4598-2-1.anc" start="23362" end="23373" sStart="null" offset="0" sid="null" wn="3" wnkey="transfer%2:38:05::" annotator="tofox" text="The whole cell extracts were separated on the 7.5% SDS PAGE and &lt;b&gt;transferred&lt;/b&gt; onto nitrocellulose membrane by electroblotting." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="16653" end="16660" sStart="null" offset="223" sid="null" wn="3" wnkey="suggest%2:32:02::" annotator="veweser" text="Cisplatin causes two types of DNA damage, DNA adducts and inter-stranded cross-linking, resulting in activation of apoptosis pathway in the target tumor cells [ 13 14 ] . Our results suggest that inhibition of tyrosine kinase activity of the potential targets by Gleevec appear to potentiate the effect of cisplatin in DNA-damage induced apoptosis in A549 cells." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="16653" end="16660" sStart="null" offset="223" sid="null" wn="3" wnkey="suggest%2:32:02::" annotator="jeneale" text="Cisplatin causes two types of DNA damage, DNA adducts and inter-stranded cross-linking, resulting in activation of apoptosis pathway in the target tumor cells [ 13 14 ] . Our results suggest that inhibition of tyrosine kinase activity of the potential targets by Gleevec appear to potentiate the effect of cisplatin in DNA-damage induced apoptosis in A549 cells." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="16653" end="16660" sStart="null" offset="223" sid="null" wn="3" wnkey="suggest%2:32:02::" annotator="cgozo" text="Cisplatin causes two types of DNA damage, DNA adducts and inter-stranded cross-linking, resulting in activation of apoptosis pathway in the target tumor cells [ 13 14 ] . Our results suggest that inhibition of tyrosine kinase activity of the potential targets by Gleevec appear to potentiate the effect of cisplatin in DNA-damage induced apoptosis in A549 cells." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="16653" end="16660" sStart="null" offset="223" sid="null" wn="3" wnkey="suggest%2:32:02::" annotator="brubin" text="Cisplatin causes two types of DNA damage, DNA adducts and inter-stranded cross-linking, resulting in activation of apoptosis pathway in the target tumor cells [ 13 14 ] . Our results suggest that inhibition of tyrosine kinase activity of the potential targets by Gleevec appear to potentiate the effect of cisplatin in DNA-damage induced apoptosis in A549 cells." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="8268" end="8274" sStart="null" offset="79" sid="r11.strong.j.0559" wn="1" wnkey="strong%3:00:00::" annotator="vebatchelder" text="In A549 cells, expression of PDGFR-?, not PDGFR-?, was detected with strong cytoplasmic and membrane staining patterns (Figure 6and 7)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="11638" end="11644" sStart="null" offset="116" sid="r9.normal.j.0231" wn="3" wnkey="normal%3:00:03::" annotator="cgozo" text="These results demonstrated that PDGFR-? expression is elevated in the tumor tissues compared to normal lung parenchyma, and the expression of PDGFR-? in tumor tissue may play important roles in tumor growth and progression." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="11271" end="11277" sStart="null" offset="18" sid="r9.normal.j.0132" wn="1" wnkey="normal%3:00:01::" annotator="brubin" text="The corresponding normal lung tissues were found to be negative for PDGFR-?." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="2874" end="2879" sStart="null" offset="99" sid="null" wn="1" wnkey="level%1:07:00::" annotator="veweser" text="We previously showed that non-small cell lung cancers express minimal (negligible) level of c-kit (Zhang, P., unpublished)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="2874" end="2879" sStart="null" offset="99" sid="null" wn="1" wnkey="level%1:07:00::" annotator="sophiavv" text="We previously showed that non-small cell lung cancers express minimal (negligible) level of c-kit (Zhang, P., unpublished)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="2874" end="2879" sStart="null" offset="99" sid="null" wn="1" wnkey="level%1:07:00::" annotator="cgozo" text="We previously showed that non-small cell lung cancers express minimal (negligible) level of c-kit (Zhang, P., unpublished)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="2874" end="2879" sStart="null" offset="99" sid="null" wn="1" wnkey="level%1:07:00::" annotator="brubin" text="We previously showed that non-small cell lung cancers express minimal (negligible) level of c-kit (Zhang, P., unpublished)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="2874" end="2879" sStart="null" offset="99" sid="null" wn="" wnkey="null" annotator="bpassonneau" text="We previously showed that non-small cell lung cancers express minimal (negligible) level of c-kit (Zhang, P., unpublished)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="2874" end="2879" sStart="null" offset="99" sid="null" wn="1" wnkey="level%1:07:00::" annotator="anfahmy" text="We previously showed that non-small cell lung cancers express minimal (negligible) level of c-kit (Zhang, P., unpublished)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="6597" end="6604" sStart="null" offset="62" sid="r9.kill.v.0979" wn="1" wnkey="kill%2:35:00::" annotator="cgozo" text="We sought to see if Gleevec can potentiate the cell killing effects of cisplatin, the leading chemotherapeutic drug for almost all advanced cancer patients." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="16946" end="16951" sStart="null" offset="83" sid="r8.1.great.j.0308" wn="3" wnkey="great%5:00:01:extraordinary:00" annotator="cgozo" text="Although the underlying mechanism of such synergism is unclear, it is of great interest to combine the two drugs in clinical lung cancer patients to see if the synergy of the two drugs exists under the physiological conditions." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="16224" end="16232" sStart="null" offset="260" sid="r11.function.n.0214" wn="7" wnkey="function%1:10:00::" annotator="vebatchelder" text="Since it has been reported that Gleevec can inhibit the function of PDGFR under the cell culture conditions, it is likely that Gleevec exerts its inhibitory effects on A549 lung cancer cells through inhibiting the PDGFR function." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="11296" end="11301" sStart="null" offset="43" sid="r10.find.v.0955" wn="8" wnkey="find%2:36:00::" annotator="cgozo" text="The corresponding normal lung tissues were found to be negative for PDGFR-?." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="17307" end="17318" sStart="null" offset="176" sid="r11.combination.n.0458" wn="1" wnkey="combination%1:14:00::" annotator="anfahmy" text="It has been widely thought, but never been proven that the specific tyrosine kinase inhibitors such as Gleevec can be used as adjuvant therapy in combination with conventional chemotherapy, because the limited clinical trial data suggests only a marginal benefits using this kind of drug to treat the cancer alone (John Rogers, WVU Cancer center, ECOG trial member, personal communication)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="6491" end="6502" sStart="null" offset="316" sid="r11.combination.n.0213" wn="7" wnkey="combination%1:04:00::" annotator="adelpriore" text="One of the major reasons of testing Gleevec for treatment of non-small cell lung carcinoma is to see if the specific tyrosine kinase inhibitor Gleevec, and other potential small molecules currently on clinical trials, can be used as an adjuvant therapeutic agent in combination with conventional chemotherapy." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="10396" end="10401" sStart="null" offset="133" sid="r10.board.n.0359" wn="1" wnkey="board%1:14:00::" annotator="cgozo" text="Using clinical diagnostic criteria, the immunostaining patterns and intensities were verified by two independent board certified surgical pathologists." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="17436" end="17444" sStart="null" offset="305" sid="r11.benefit.n.0656" wn="2" wnkey="benefit%1:07:00::" annotator="anfahmy" text="It has been widely thought, but never been proven that the specific tyrosine kinase inhibitors such as Gleevec can be used as adjuvant therapy in combination with conventional chemotherapy, because the limited clinical trial data suggests only a marginal benefits using this kind of drug to treat the cancer alone (John Rogers, WVU Cancer center, ECOG trial member, personal communication)." />
    <s path="[OANC]/data/written_2/technical/biomed/1476-4598-2-1.anc" start="5671" end="5677" sStart="null" offset="55" sid="r9.appear.v.0581" wn="1" wnkey="appear%2:39:00::" annotator="veweser" text="The IC50 concentration for A549 cells didn't appear to have inhibitory effects on human 293 cells (Figure 3)." />
  </sentences>
</list>